Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
30 06 2021
Historique:
received: 15 12 2020
accepted: 20 06 2021
entrez: 1 7 2021
pubmed: 2 7 2021
medline: 6 8 2021
Statut: epublish

Résumé

We investigated pathogenic DYRK1B variants causative of abdominal obesity-metabolic syndrome 3 (AOMS3) in a group of patients originally diagnosed with type 2 diabetes. All DYRK1B exons were analyzed in a sample of 509 unrelated adults with type 2 diabetes and 459 controls, all belonging to the DMS1 SIGMA-cohort (ExAC). We performed in silico analysis on missense variants using Variant Effect Predictor software. To evaluate co-segregation, predicted pathogenic variants were genotyped in other family members. We performed molecular dynamics analysis for the co-segregating variants. After filtering, Mendelian genotypes were confirmed in two probands bearing two novel variants, p.Arg252His and p.Lys68Gln. Both variants co-segregated with the AOMS3 phenotype in classic dominant autosomal inheritance with full penetrance. In silico analysis revealed impairment of the DYRK1B protein function by both variants. For the first time, we describe age-dependent variable expressivity of this entity, with central obesity and insulin resistance apparent in childhood; morbid obesity, severe hypertriglyceridemia, and labile type 2 diabetes appearing before 40 years of age; and hypertension emerging in the fifth decade of life. We also report the two youngest individuals suffering from AOMS3. Monogenic forms of metabolic diseases could be misdiagnosed and should be suspected in families with several affected members and early-onset metabolic phenotypes that are difficult to control. Early diagnostic strategies and medical interventions, even before symptoms or complications appear, could be useful.

Sections du résumé

BACKGROUND
We investigated pathogenic DYRK1B variants causative of abdominal obesity-metabolic syndrome 3 (AOMS3) in a group of patients originally diagnosed with type 2 diabetes. All DYRK1B exons were analyzed in a sample of 509 unrelated adults with type 2 diabetes and 459 controls, all belonging to the DMS1 SIGMA-cohort (ExAC). We performed in silico analysis on missense variants using Variant Effect Predictor software. To evaluate co-segregation, predicted pathogenic variants were genotyped in other family members. We performed molecular dynamics analysis for the co-segregating variants.
RESULTS
After filtering, Mendelian genotypes were confirmed in two probands bearing two novel variants, p.Arg252His and p.Lys68Gln. Both variants co-segregated with the AOMS3 phenotype in classic dominant autosomal inheritance with full penetrance. In silico analysis revealed impairment of the DYRK1B protein function by both variants. For the first time, we describe age-dependent variable expressivity of this entity, with central obesity and insulin resistance apparent in childhood; morbid obesity, severe hypertriglyceridemia, and labile type 2 diabetes appearing before 40 years of age; and hypertension emerging in the fifth decade of life. We also report the two youngest individuals suffering from AOMS3.
CONCLUSIONS
Monogenic forms of metabolic diseases could be misdiagnosed and should be suspected in families with several affected members and early-onset metabolic phenotypes that are difficult to control. Early diagnostic strategies and medical interventions, even before symptoms or complications appear, could be useful.

Identifiants

pubmed: 34193236
doi: 10.1186/s13023-021-01924-z
pii: 10.1186/s13023-021-01924-z
pmc: PMC8247206
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

291

Références

J Comput Chem. 2006 Nov 15;27(14):1765-8
pubmed: 16917862
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
Int J Obes (Lond). 2020 Apr;44(4):830-841
pubmed: 30926952
Sci Rep. 2017 Jul 25;7(1):6420
pubmed: 28743892
J Mol Graph Model. 2002 Aug;21(1):47-9
pubmed: 12413030
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
N Engl J Med. 2014 May 15;370(20):1909-1919
pubmed: 24827035
Metab Syndr Relat Disord. 2018 Oct;16(8):395-405
pubmed: 30063173
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
Salud Publica Mex. 2010;52 Suppl 1:S11-8
pubmed: 20585723
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
J Biol Chem. 2009 Jan 2;284(1):478-485
pubmed: 19001369
Methods Mol Biol. 2018;1706:3-16
pubmed: 29423790
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
JCI Insight. 2020 Jan 16;5(1):
pubmed: 31821176
Nature. 2014 Feb 6;506(7486):97-101
pubmed: 24390345
Biochem Biophys Res Commun. 2003 Jan 17;300(3):764-9
pubmed: 12507516
N Engl J Med. 2014 Aug 21;371(8):784-5
pubmed: 25140973
Hormones (Athens). 2018 Sep;17(3):299-313
pubmed: 30171523
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):365-367
pubmed: 28587579

Auteurs

Elvia C Mendoza-Caamal (EC)

Clinical Area, National Institute of Genomic Medicine, SS, Mexico City, Mexico.

Francisco Barajas-Olmos (F)

Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, SS. Periférico Sur 4809, Colonia Arenal Tepepan, Alcaldía Tlalpan, C.P. 14610, Mexico City, Mexico.

Elaheh Mirzaeicheshmeh (E)

Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, SS. Periférico Sur 4809, Colonia Arenal Tepepan, Alcaldía Tlalpan, C.P. 14610, Mexico City, Mexico.

Ian Ilizaliturri-Flores (I)

SEPI-UPIIH, National Polytechnic Institute, Pachuca, Hidalgo, Mexico.

Carlos A Aguilar-Salinas (CA)

Metabolic Diseases Research Unit, National Institute of Medical Science and Nutrition Salvador Zubirán, Mexico City, Mexico.
Department of Endocrinology and Metabolism, National Institute of Medical Science and Nutrition Salvador Zubirán, Mexico City, Mexico.
Direction of Nutrition, National Institute of Medical Science and Nutrition Salvador Zubirán, Mexico City, Mexico.
School of Medicine and Health Sciences, Monterrey Institute of Technology, Mexico City, Mexico.

Donaji V Gómez-Velasco (DV)

Metabolic Diseases Research Unit, National Institute of Medical Science and Nutrition Salvador Zubirán, Mexico City, Mexico.
Department of Endocrinology and Metabolism, National Institute of Medical Science and Nutrition Salvador Zubirán, Mexico City, Mexico.
Direction of Nutrition, National Institute of Medical Science and Nutrition Salvador Zubirán, Mexico City, Mexico.
School of Medicine and Health Sciences, Monterrey Institute of Technology, Mexico City, Mexico.

Isabel Cicerón-Arellano (I)

Clinical Area, National Institute of Genomic Medicine, SS, Mexico City, Mexico.

Adriana Reséndiz-Rodríguez (A)

Clinical Area, National Institute of Genomic Medicine, SS, Mexico City, Mexico.

Angélica Martínez-Hernández (A)

Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, SS. Periférico Sur 4809, Colonia Arenal Tepepan, Alcaldía Tlalpan, C.P. 14610, Mexico City, Mexico.

Cecilia Contreras-Cubas (C)

Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, SS. Periférico Sur 4809, Colonia Arenal Tepepan, Alcaldía Tlalpan, C.P. 14610, Mexico City, Mexico.

Sergio Islas-Andrade (S)

Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, SS. Periférico Sur 4809, Colonia Arenal Tepepan, Alcaldía Tlalpan, C.P. 14610, Mexico City, Mexico.

Carlos Zerrweck (C)

Integral Clinic of Surgery for Obesity and Metabolic Diseases, General Hospital Tláhuac, SS, Mexico City, Mexico.

Humberto García-Ortiz (H)

Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, SS. Periférico Sur 4809, Colonia Arenal Tepepan, Alcaldía Tlalpan, C.P. 14610, Mexico City, Mexico.

Lorena Orozco (L)

Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, SS. Periférico Sur 4809, Colonia Arenal Tepepan, Alcaldía Tlalpan, C.P. 14610, Mexico City, Mexico. lorozco@inmegen.gob.mx.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH